cmAngio® vs EchoNext
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography screenings for early cardiovascular risk assessment in women. This tool is ideal for radiology departments and OB/GYN practices seeking to identify Breast Arterial Calcifications (BAC) as a potential indicator of cardiovascular disease without requiring additional patient procedures or radiation exposure. It seamlessly integrates with current imaging workflows, providing valuable insights for proactive patient management.
View cmAngio® →Choose EchoNext if…
Choose EchoNext if your focus is on broad, non-invasive screening for hidden structural heart disease using standard ECGs. This tool is best suited for cardiology, family medicine, and internal medicine practices looking to identify risks for conditions like heart failure, valve disease, and pulmonary hypertension from routine ECGs. Its accessibility through the OpenEvidence platform makes it a strong choice for diverse clinical settings, from major hospitals to community practices, aiming for early detection and intervention.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | EchoNext |
|---|---|---|
| Pricing | Contact for details | Starts at $600/month |
| Deployment | Cloud-based (inferred from similar CureMetrix products) | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®cmAngio boasts quick and easy installation (less than an hour) and compatibility with any DICOM-compliant viewer, suggesting a straightforward integration into existing radiology workflows. EchoNext, while available through the OpenEvidence platform, doesn't provide specific details on its ease of installation or direct integration with various clinical systems beyond that platform.
Clinical Value
EchoNextEchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI. It has also been credited with leading to the first peer-reviewed heart transplant attributable to AI-based disease detection. While cmAngio provides valuable insights into cardiovascular risk through BAC detection, its direct impact on patient outcomes, such as preventing major adverse cardiovascular events, is still an area of ongoing research and validation.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts. In contrast, cmAngio's pricing is not publicly available, requiring direct contact with the vendor, which can make initial cost assessment challenging for potential buyers.
Enterprise Readiness
TieBoth tools are FDA-cleared and HIPAA-compliant, indicating adherence to critical regulatory and security standards for enterprise deployment. cmAngio is cloud-based and compatible with DICOM-compliant viewers, while EchoNext is available through the OpenEvidence platform, suggesting different but equally valid approaches to enterprise integration.
Innovation
EchoNextEchoNext is highlighted as the world's first FDA-approved AI detection tool to analyze ECGs for hidden structural heart disease, representing a novel application of AI in cardiology. It also boasts a broader range of detected conditions (heart failure, valve disease, pulmonary hypertension) from a single, widely available test. While cmAngio is innovative in its use of AI for BAC detection on mammograms, EchoNext's approach to leveraging a common, inexpensive test for a wider array of critical cardiac conditions appears to be a more significant leap in diagnostic innovation.
Support & Docs
TieNeither tool provides explicit details on their support channels or documentation availability in the provided information. Therefore, it is not possible to definitively pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | EchoNext |
|---|---|---|
| Name | cmAngiou00ae | EchoNext |
| Company | CureMetrix | Pathway Labs |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-based detection of Breast Arterial Calcifications (BAC); Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams; Provides visualization of BAC location on a scorecard; Enables BAC identification and reporting without additional radiation or procedures; Compatible with any DICOM-compliant viewer; Adjustable operating point to meet clinical goals; Quick and easy installation (less than an hour); Cybersecure and HIPAA-compliant | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and EchoNext.